Filing Details
- Accession Number:
- 0001415889-23-006694
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-04-19 16:09:01
- Reporting Period:
- 2023-04-17
- Accepted Time:
- 2023-04-19 16:09:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1070081 | Ptc Therapeutics Inc. | PTCT | Pharmaceutical Preparations (2834) | 043416587 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1578852 | Elliott Mark Boulding | C/O Ptc Therapeutics, Inc. 100 Corporate Court South Plainfield NJ 07080 | Exec. Vp And Clo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-04-17 | 3,292 | $30.86 | 78,670 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-04-17 | 3,292 | $51.42 | 75,378 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-04-17 | 58,631 | $30.86 | 134,009 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-04-17 | 58,631 | $51.42 | 75,378 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-04-17 | 3,292 | $30.86 | 3,292 | $30.86 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-04-17 | 58,631 | $30.86 | 58,631 | $30.86 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 58,631 | 2026-01-03 | No | 4 | M | Direct | |
| 0 | 2026-01-03 | No | 4 | M | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | $51.00 | 2025-01-01 | 85,600 | 85,600 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $33.02 | 2029-01-21 | 72,500 | 72,500 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $33.02 | 2029-01-21 | 17,500 | 17,500 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $51.16 | 2030-01-28 | 59,500 | 59,500 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $66.49 | 2031-01-05 | 59,500 | 59,500 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $38.10 | 2032-01-06 | 54,000 | 54,000 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $39.42 | 2033-01-04 | 36,250 | 36,250 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2025-01-01 | 85,600 | 85,600 | Direct |
| 2029-01-21 | 72,500 | 72,500 | Direct |
| 2029-01-21 | 17,500 | 17,500 | Direct |
| 2030-01-28 | 59,500 | 59,500 | Direct |
| 2031-01-05 | 59,500 | 59,500 | Direct |
| 2032-01-06 | 54,000 | 54,000 | Direct |
| 2033-01-04 | 36,250 | 36,250 | Direct |
Footnotes
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 2, 2022.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.00 to $51.79 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.00 to $51.825 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Currently exercisable.
- This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
- This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.
- This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.
- This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
Billionaire Hedge Funds
